Nwam LLC Takes Position in Insmed Incorporated (NASDAQ:INSM)

Nwam LLC acquired a new stake in Insmed Incorporated (NASDAQ:INSM) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 36,096 shares of the biopharmaceutical company’s stock, valued at approximately $2,492,000.

Other hedge funds also recently modified their holdings of the company. V Square Quantitative Management LLC boosted its position in shares of Insmed by 60.3% in the fourth quarter. V Square Quantitative Management LLC now owns 659 shares of the biopharmaceutical company’s stock valued at $45,000 after acquiring an additional 248 shares during the period. Spire Wealth Management bought a new stake in shares of Insmed in the fourth quarter valued at approximately $47,000. Venturi Wealth Management LLC bought a new stake in shares of Insmed in the fourth quarter valued at approximately $86,000. Quantbot Technologies LP bought a new stake in shares of Insmed in the third quarter valued at approximately $133,000. Finally, Avior Wealth Management LLC bought a new stake in shares of Insmed in the fourth quarter valued at approximately $157,000.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on INSM. Wells Fargo & Company increased their price objective on Insmed from $85.00 to $107.00 and gave the company an “overweight” rating in a research report on Wednesday, February 19th. Royal Bank of Canada began coverage on Insmed in a research report on Tuesday. They issued an “outperform” rating and a $100.00 target price for the company. Stifel Nicolaus reduced their target price on Insmed from $97.00 to $96.00 and set a “buy” rating for the company in a research report on Friday, February 21st. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Insmed in a research report on Wednesday, February 19th. Finally, Truist Financial raised their target price on Insmed from $105.00 to $108.00 and gave the stock a “buy” rating in a research report on Friday, February 21st. One investment analyst has rated the stock with a sell rating and sixteen have issued a buy rating to the stock. According to MarketBeat.com, Insmed currently has an average rating of “Moderate Buy” and a consensus price target of $91.60.

Insider Activity

In other news, insider Orlov S. Nicole Schaeffer sold 91,140 shares of the firm’s stock in a transaction on Thursday, January 30th. The stock was sold at an average price of $80.00, for a total value of $7,291,200.00. Following the completion of the sale, the insider now directly owns 97,083 shares in the company, valued at approximately $7,766,640. This trade represents a 48.42 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CEO William Lewis sold 18,750 shares of the firm’s stock in a transaction dated Thursday, December 19th. The shares were sold at an average price of $69.91, for a total value of $1,310,812.50. Following the completion of the transaction, the chief executive officer now owns 384,960 shares in the company, valued at approximately $26,912,553.60. This represents a 4.64 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 532,207 shares of company stock worth $41,400,465. 4.60% of the stock is owned by corporate insiders.

Insmed Stock Performance

Insmed stock opened at $79.05 on Friday. Insmed Incorporated has a 52-week low of $21.92 and a 52-week high of $84.91. The firm has a market capitalization of $14.31 billion, a P/E ratio of -14.14 and a beta of 1.11. The company has a debt-to-equity ratio of 2.03, a current ratio of 6.37 and a quick ratio of 5.99. The stock has a fifty day moving average price of $74.66 and a two-hundred day moving average price of $73.73.

Insmed (NASDAQ:INSM) last announced its earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.32) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.17) by ($0.15). Insmed had a negative net margin of 251.24% and a negative return on equity of 4,773.73%. The business had revenue of $104.44 million during the quarter, compared to analyst estimates of $102.31 million. As a group, analysts anticipate that Insmed Incorporated will post -4.56 EPS for the current fiscal year.

Insmed Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.